Loxo Oncology at Lilly and Merus entered an exclusive research collaboration and license agreement for up to three CD3-redirecting bispecific antibodies leveraging Merus' Biclonics platform. Merus received $40M upfront and a $20M equity investment, plus eligibility for up to $540M in development/commercialization milestones per product (~$1.6B total) and tiered royalties.
Key facts
AnnouncedJan 19, 2021
ClosedJan 18, 2021
Deal value$1.7B
Deal typeLicensing/Option
Therapeutic areaOncology (solid tumors)
IndicationsOncology (solid tumors)
Key assetsUp to three CD3-engaging T-cell redirecting bispecific antibodies